The Analyst Landscape: 21 Takes On Humana
Portfolio Pulse from Benzinga Insights
21 analysts have recently updated their ratings on Humana (NYSE:HUM), showing a diverse range of perspectives from bullish to bearish. The average 12-month price target is now $428.95, a 15.62% decline from the previous average, with adjustments made by analysts from firms including Wells Fargo, Goldman Sachs, and Barclays. Humana's financial performance indicates a revenue growth rate of 17.93% as of December 31, 2023, but challenges in net margin and debt management are noted. The company's focus on government-sponsored programs and healthcare services positions it uniquely in the health insurance sector.

April 08, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Humana's stock may experience volatility due to the mixed analyst ratings and the significant adjustment in the average price target. The company's strong revenue growth contrasts with concerns over net margin and debt management.
The diverse analyst perspectives and the downward adjustment in the average price target could lead to short-term volatility in Humana's stock price. However, the company's strong revenue growth indicates underlying strength, potentially offsetting concerns over profitability and debt, leading to a neutral short-term impact.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100